Primary Human Trabecular Meshwork Model for Pseudoexfoliation.
Amyloid beta-Peptides
/ adverse effects
Cell Survival
/ drug effects
Epithelial-Mesenchymal Transition
/ drug effects
Exfoliation Syndrome
/ complications
Gene Expression Regulation
/ drug effects
Glaucoma
/ complications
Humans
Primary Cell Culture
/ methods
Protein Aggregates
/ drug effects
Trabecular Meshwork
/ metabolism
Transforming Growth Factor beta1
/ genetics
TGF-β1
fibrosis
human trabecular meshwork
in vitro cell line model
pseudoexfoliation
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
07 12 2021
07 12 2021
Historique:
received:
06
11
2021
revised:
29
11
2021
accepted:
01
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
21
1
2022
Statut:
epublish
Résumé
The lack of an animal model or an in vitro model limits experimental options for studying temporal molecular events in pseudoexfoliation syndrome (PXF), an age related fibrillopathy causing trabecular meshwork damage and glaucoma. Our goal was to create a workable in vitro model of PXF using primary human TM (HTM) cell lines simulating human disease. Primary HTM cells harvested from healthy donors (
Identifiants
pubmed: 34943956
pii: cells10123448
doi: 10.3390/cells10123448
pmc: PMC8700223
pii:
doi:
Substances chimiques
Amyloid beta-Peptides
0
Protein Aggregates
0
TGFB1 protein, human
0
Transforming Growth Factor beta1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust/DBT India Alliance
ID : IA/CPHI/15/1/502031
Références
Cancer Res. 2011 Aug 1;71(15):5296-306
pubmed: 21653678
PLoS One. 2019 Mar 6;14(3):e0212569
pubmed: 30840655
Clin Ophthalmol. 2021 Jul 14;15:3027-3039
pubmed: 34285469
Curr Opin Rheumatol. 2012 Nov;24(6):663-8
pubmed: 22918530
Medicina (Kaunas). 2019 Jun 17;55(6):
pubmed: 31212881
Respir Res. 2002;3:1
pubmed: 11806836
Am J Pathol. 2010 Jun;176(6):2868-79
pubmed: 20395431
Future Oncol. 2012 Jun;8(6):713-22
pubmed: 22764769
Prog Mol Biol Transl Sci. 2015;134:301-14
pubmed: 26310162
Fold Des. 1998;3(1):R9-23
pubmed: 9502314
Hepatology. 2006 Dec;44(6):1487-501
pubmed: 17133487
Mol Vis. 2012;18:431-8
pubmed: 22355254
Biochem Biophys Res Commun. 2002 Jun 28;294(5):1155-60
pubmed: 12074598
PLoS One. 2017 Aug 10;12(8):e0182571
pubmed: 28797085
Curr Opin Ophthalmol. 2008 Mar;19(2):95-101
pubmed: 18301281
Exp Eye Res. 2001 Dec;73(6):765-80
pubmed: 11846508
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195692
Invest Ophthalmol Vis Sci. 1995 Aug;36(9):1750-64
pubmed: 7635652
J Glaucoma. 2014 Oct-Nov;23(8 Suppl 1):S12-4
pubmed: 25275897
Int J Mol Sci. 2020 Jun 16;21(12):
pubmed: 32560057
Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1205-14
pubmed: 19029039
Mol Med Rep. 2020 Jan;21(1):173-180
pubmed: 31746423
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
PLoS One. 2021 Apr 29;16(4):e0249759
pubmed: 33914756
Cell Tissue Res. 2016 Sep;365(3):495-506
pubmed: 27461257
Exp Eye Res. 2014 Jan;118:72-9
pubmed: 24291802
Prog Retin Eye Res. 2017 Sep;60:44-65
pubmed: 28807717
Clin Ophthalmol. 2020 Oct 05;14:3025-3038
pubmed: 33116354
Turk J Biol. 2019 Apr 5;43:89-98
pubmed: 31410078
Clin Ophthalmol. 2014 Jan 29;8:305-9
pubmed: 24511224
Ophthalmic Res. 2017;57(2):77-86
pubmed: 27618367
Front Oncol. 2020 Apr 07;10:499
pubmed: 32318352